Last reviewed · How we verify
Moderate to severe chronic spontaneous urticaria in infants and children
Approved treatments
- Chronic- PF-06480605 450 mg SC Q4W · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe chronic spontaneous urticaria in infants and children patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe chronic spontaneous urticaria in infants and children treatment landscape brief
- Moderate to severe chronic spontaneous urticaria in infants and children treatment updates RSS
Frequently asked questions about Moderate to severe chronic spontaneous urticaria in infants and children
What drugs treat Moderate to severe chronic spontaneous urticaria in infants and children?
Tracked treatments include Chronic- PF-06480605 450 mg SC Q4W.
What is the treatment for Moderate to severe chronic spontaneous urticaria in infants and children?
Standard treatment for Moderate to severe chronic spontaneous urticaria in infants and children includes Chronic- PF-06480605 450 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe chronic spontaneous urticaria in infants and children patent cliff · Moderate to severe chronic spontaneous urticaria in infants and children CI report
- Treatment: Chronic- PF-06480605 450 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing